Home
About
Overview
Sharing Data
ORCID
Help
History (5)
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
Correction: 2'-Hydroxyflavanone effectively targets RLIP76-mediated drug transport and regulates critical signaling networks in breast cancer.
Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications.
Molecular and cellular biology of small cell lung cancer.
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready?
ALK-Directed Therapy in Non-NSCLC Malignancies: Are We Ready? JCO Precis Oncol. 2021 11; 5:767-770.
View in:
PubMed
subject areas
Carcinoma, Non-Small-Cell Lung
Humans
Lung Neoplasms
authors with profiles
Ravi Salgia